3月31日晚间,成都先导(688222.SH)公告称,公司正在筹划以现金方式受让股权的方式合计取得南京海纳医药科技股份有限公司(简称“海纳医药”)约65%的股权。公告显示,本次交易预计构成重大资产重组,但不涉及公司发行股份,也不会导致公司控制权的变更。南财快讯记者注意到,海纳医药曾“闯关”创业板IPO,后于2024年6月撤单。招股书显示,该公司是一家主要从事仿制药、改良型新药研发的一体化全流程医药...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.